Kate Hillier

Kate’s representative experience includes advising:

• Alumis on its 2025 collaboration and licensing agreement with Kaken to develop, manufacture, and commercialize ESK-001, a highly selective, next-generation oral TYK2 inhibitor, for dermatology (and potentially other) indications in Japan, including US$40 million in upfront and near-term co-development payments and up to US$140 million in milestone and other payments, plus tiered royalties*
• Merus NV on its:
  • 2025 research collaboration and license agreement with Biohaven to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus’ leading Biclonics technology platform, and Biohaven’s next-generation ADC conjugation and payload platform technologies*
  • 2024 multiprogram collaboration with Gilead to discover and develop novel dual tumor-associated antigens targeting trispecific antibodies, including a total of US$81 million in upfront cash and equity and up to US$1.5 billion in potential milestones, plus tiered royalties and a potential co-development option*
  • 2020 collaboration and exclusive license agreement with Eli Lilly to develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies, including US$60 million in aggregate upfront cash and equity investment and up to US$1.6 billion in milestone payments, plus royalties*
• Flare Therapeutics on its 2024 strategic discovery collaboration with Roche, leveraging FlareTx’s proteomic and mass spectrometry platform to discover novel small molecule drugs aimed at previously undrugged transcription factor targets in oncology, with US$70 million upfront and up to US$1.8 billion in milestones, plus royalties, and with FlareTx retaining a right to co-fund development in one program in exchange for a royalty uplift*
• Personalis on its 2024 multi-year extension of its diagnostics collaboration with Moderna to utilize Personalis’ ImmunoID NeXT Platform and technology for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT), being jointly developed by Merck and Moderna*
• SystImmune on its 2023 global co-development and co-commercialization collaboration with Bristol Myers Squibb (BMS) for SystImmune’s novel antibody-drug conjugate (ADC) compound BL-B01D1, with an US$800 million upfront and an additional US$500 million in near-term payments, with up to an additional US$7.1 billion in milestone payments, plus profit share*
• Cellares on its 2024 global collaboration with BMS for capacity reservation and integrated cell therapy manufacturing and supply of BMS’s chimeric antigen receptor T-cell (CAR-T) therapies on Cellares’ Cell Shuttle platform, including US$380 million in upfront and milestone payments, along with an ongoing supply relationship*
• HAYA Therapeutics SA on its 2024 multi-year collaboration agreement with Eli Lilly to apply HAYA’s AI-enabled advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions, including an equity investment, with up to an aggregate US$1 billion in pre-clinical, clinical and commercial milestone payments*
• Serina Therapeutics on its 2024 collaboration with Enable Injections to develop and commercialize a novel delivery system for Serina’s SER-252 compound for advanced Parkinson’s disease*
• Scripps Research on its:
  • 2023 expanded collaboration with AbbVie to advance several preclinical and early-stage clinical assets*
  • 2022 global collaboration with AbbVie to develop and commercialize novel antiviral therapeutics for the treatment of COVID-19*
• Vir Biotechnology on:
  • The expansion of its 2020 collaboration with GSK to include multiple respiratory viral diseases, including Vir’s influenza program, as well as additional antibody and expanded functional genomics programs, with an upfront payment of US$225 million and US$120 million in additional equity, plus option and milestone payments and profit sharing on all programs*
  • A multiprogram profit-sharing COVID collaboration with GSK to develop multiple therapeutic approaches to COVID-19, including antibody, vaccine and functional genomics programs*
• Sana Biotechnology on its 2021 agreement with Beam Therapeutics for commercial rights to Beam’s CRISPR-Cas12b gene-editing system in connection with multiple Sana development programs*
• 23andMe on its strategic collaboration with GSK for the research and development of novel targets leveraging 23andMe’s novel database and equity investment, as well as an ongoing advisory role with respect to multiple amendments to the collaboration to address different programs under development*
• ArsenalBio on its multiyear discovery collaboration with BMS to advance next-generation T-cell therapies for the treatment of solid tumors, for a US$70 million upfront payment and substantial additional development, regulatory and commercial milestone payments, plus royalties*
• CStone Pharmaceuticals on its US$200 million investment by a Pfizer affiliate and subsequent strategic collaboration between CStone and Pfizer Investment to develop and commercialize CStone’s sugemalimab in mainland China, for up to US$280 million in milestone payments, plus royalties, in addition to a collaboration on other late-stage assets in China*
• Bicycle Therapeutics on its strategic collaboration agreement with Genentech to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies, for up to US$1.7 billion in upfront and milestone payments, plus royalties*
• Harpoon Therapeutics in its:
  • Licensing and option collaboration with AbbVie to advance Harpoon’s BCMA-targeting trispecific activating construct, totaling up to US$510 million in upfront, option, and milestone payments, plus royalties on product sales*
  • Major expansion of its existing discovery collaboration with AbbVie to include up to six additional targets, for up to US$310 million per target in upfront and milestone payments, plus royalties*
• Adaptive Biotechnologies on its worldwide collaboration and license transaction with Genentech to develop and commercialize novel neoantigen directed T-cell therapies in a range of cancers, including transformational personalized therapies directed to individual patients and cancers, for a US$300 million upfront payment and up to US$2 billion in potential milestone payments, plus royalties*
• Ionis Pharmaceuticals on its strategic collaboration with Biogen to develop novel antisense drug candidates in neurological diseases directed to targets selected by Biogen, including a US$375 million upfront cash payment and purchase of US$625 million in Ionis stock, as well as milestones and royalty payments on product sales*
• Allogene Therapeutics and its investors (including TPG Capital) on the carve out from Pfizer of its Allogeneic T-cell therapy business, including an equity raise of US$300 million*

*Matter handled prior to joining Latham